Inventor · disambiguated record
Mathieu Blery
Also filed as: BLERY MATHIEU
14 granted patents·11 pending applications·97 citations·filing 2006–2024
91Inventor score
Files withINNATE PHARMA20INNATE PHARMA SA2BRISTOL MYERS SQUIBB CO1ROMAGNE FRANCOIS1UNIV BREST BRETAGNE OCCIDENTALE1
Top patents by PatentIndex Score
25 records- 0195US11572410B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2020·Granted Feb 7, 2023·3 cites·5 claims
- 0295US10329348B2Treatment of cancers using anti-NKG2A agentsINNATE PHARMA·Filed 2015·Granted Jun 25, 2019·16 cites·15 claims
- 0393US10711063B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2015·Granted Jul 14, 2020·8 cites·13 claims
- 0493US9447185B2Compositions and methods for treating proliferative disordersROMAGNE FRANCOIS·Filed 2006·Granted Sep 20, 2016·46 cites·6 claims
- 0592US10676523B2Treatment regimens using anti-NKG2A antibodiesINNATE PHARMA·Filed 2015·Granted Jun 9, 2020·7 cites·10 claims
- 0689US10870700B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2017·Granted Dec 22, 2020·6 cites·16 claims
- 0787US11225519B2Treatment of cancers using anti-NKG2A agentsINNATE PHARMA·Filed 2019·Granted Jan 18, 2022·3 cites·18 claims
- 0884US2024368281A1Treatment regimens using anti-nkg2a antibodiesINNATE PHARMA·Filed 2024·Application pending·0 cites
- 0982US10344087B2Treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2014·Granted Jul 9, 2019·3 cites·7 claims
- 1082US2024425586A1Treatment of peripheral t cell lymphomaINNATE PHARMA·Filed 2024·Application pending·0 cites
- 1178US11377492B2NKp46 binding agentsINNATE PHARMA·Filed 2018·Granted Jul 5, 2022·1 cites·16 claims
- 1277US10577416B2Mica binding agentsINNATE PHARMA SA·Filed 2013·Granted Mar 3, 2020·3 cites·3 claims
- 1376US2023235060A1Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2023·Application pending·0 cites
- 1474US12037392B2Treatment regimens using anti-NKG2A antibodiesINNATE PHARMA·Filed 2021·Granted Jul 16, 2024·0 cites·10 claims
- 1574US2023303691A1Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2023·Application pending·0 cites
- 1671US11999784B2Treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2019·Granted Jun 4, 2024·0 cites·1 claims
- 1770US12365731B2NKp46 binding agentsINNATE PHARMA·Filed 2022·Granted Jul 22, 2025·0 cites·9 claims
- 1867US10494433B2Combination of anti-KIR and anti-CS1 antibodies to treat multiple myelomaBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Dec 3, 2019·1 cites·14 claims
- 1967US2020299383A1Treatment regimens using anti-nkg2a antibodiesINNATE PHARMA·Filed 2020·Application pending·0 cites
- 2064US2021122821A1Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2020·Application pending·0 cites
- 2158US2020299380A1Mica binding agentsINNATE PHARMA·Filed 2020·Application pending·0 cites
- 2248US2024083990A1Novel stim1 splicing variants and uses thereofUNIV BREST BRETAGNE OCCIDENTALE·Filed 2022·Application pending·0 cites
- 2343US2008196111A1Expression Vectors and Methods for Obtaining Nk Cell Specific ExpressionINNATE PHARMA SA·Filed 2006·Application pending·0 cites
- 2440US2017267764A1Anti-mica antibodiesINNATE PHARMA·Filed 2017·Application pending·0 cites
- 2538US2020023071A1Immunomodulatory antibody drug conjugates binding to a human mica polypeptideINNATE PHARMA·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mathieu Blery files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →